Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep 15;90(6):356-358.
doi: 10.1016/j.biopsych.2021.06.014.

mGlu3 Metabotropic Glutamate Receptors-New Hope for Pharmacotherapy of Schizophrenia

Mariacristina Mazzitelli  1 , Volker Neugebauer  2
Affiliations
Comment

mGlu3 Metabotropic Glutamate Receptors-New Hope for Pharmacotherapy of Schizophrenia

Mariacristina Mazzitelli et al. Biol Psychiatry. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures

The authors report no biomedical financial interests or potential conflicts of interest.

Figures

Figure 1.
Figure 1.. mGlu3- and mGlu5-mediated hippocampal synaptic plasticity.
(A) In the absence of mGlu3 activation, mGlu5 interacts with Homer protein to engage the PI3K/Akt/GSK3β pathway, resulting in the internalization of AMPA receptors and generation of LTD. (B) In the PCP model of schizophrenia, NMDA receptor hypofunction has been linked to increased inhibitory tone onto the hippocampal pyramidal cells, resulting in impaired LTP (10). (C) Activation of mGlu3 switches mGlu5-mediated plasticity towards the generation of LTP by promoting endocannabinoid-mediated inhibition of GABAergic interneurons (disinhibition) to drive hippocampal pyramidal cells, resulting in increased NMDA receptor function. mGlu3 and mGlu5, metabotropic glutamate receptor subtypes 3 and 5; PI3K, phosphoinositide 3-kinase; Akt, known as protein kinase B (PKB); GSK3β, glycogen synthase kinase 3β; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor; LTD, long-term depression; NMDA, N-methyl-D-aspartate receptor; LTP, long-term potentiation; 2-AG, 2-arachidonoylglycerol; CB1, cannabinoid receptor type 1. Grey indicates hypofunction.
See this image and copyright information in PMC

Comment on

References

    1. Maksymetz J, Moran SP, Conn PJ (2017): Targeting metabotropic glutamate receptors for novel treatments of schizophrenia. Mol Brain. 10:15. - PMC - PubMed
    1. Saini SM, Mancuso SG, Mostaid MS, Liu C, Pantelis C, Everall IP, et al. (2017): Meta-analysis supports GWAS-implicated link between GRM3 and schizophrenia risk. Transl Psychiatry. 7:e1196. - PMC - PubMed
    1. Tamaru Y, Nomura S, Mizuno N, Shigemoto R (2001): Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience. 106:481–503. - PubMed
    1. Stansley BJ, Conn PJ (2019): Neuropharmacological Insight from Allosteric Modulation of mGlu Receptors. Trends Pharmacol Sci. 40:240–252. - PMC - PubMed
    1. Dogra S, Stansley BJ, Xiang Z, Qian W, Gogliotti RG, Nicoletti F, et al. (2021): Activating mGlu3 Metabotropic Glutamate Receptors Rescues Schizophrenia-like Cognitive Deficits Through Metaplastic Adaptations Within the Hippocampus. Biol Psychiatry. - PMC - PubMed

Publication types

MeSH terms

Substances